(Press-News.org) James Rucker, a psychiatrist and honorary lecturer at the Institute of Psychiatry, Psychology and Neuroscience, King's College London, describes how these drugs "were extensively used and researched in clinical psychiatry" before their prohibition in 1967.
He explains that many trials of psychedelics published before prohibition, in the 1950s and 1960s, suggested "beneficial change in many psychiatric disorders".
However, research ended after 1967. In the UK psychedelic drugs were legally classified as schedule 1 class A drugs - that is, as having "no accepted medical use and the greatest potential for harm, despite the research evidence to the contrary," he writes.
Rucker points out that psychedelics remain more legally restricted than heroin and cocaine. "But no evidence indicates that psychedelic drugs are habit forming; little evidence indicates that they are harmful in controlled settings; and much historical evidence shows that they could have use in common psychiatric disorders."
In fact, recent studies indicate that psychedelics have "clinical efficacy in anxiety associated with advanced cancer, obsessive compulsive disorder, tobacco and alcohol addiction, and cluster headaches," he writes.
And he explains that, at present, larger clinical studies on psychedelics are made "almost impossible by the practical, financial and bureaucratic obstacles" imposed by their schedule 1 classification. Currently, only one manufacturer in the world produces psilocybin for trial purposes, he says, at a "prohibitive" cost of £100,000 for 1 g (50 doses).
In the UK, to hold a schedule 1 drug, institutions require a license, which costs about £5,000, he adds. Only four hospitals currently hold such licenses, which come with regular police or home office inspections and onerous rules on storage and transport.
This, he argues, "means that clinical research using psychedelics costs 5-10 times that of research into less restricted (but more harmful) drugs such as heroin."
As a result, "almost all grant funders are uncomfortable funding research into psychedelics," writes Rucker, while prohibition as a condition of UN membership is "arguably causing more harm than it prevents."
He concludes that psychedelics are neither harmful nor addictive compared with other controlled substances, and he calls on the UK Advisory Council on the Misuse of Drugs and the 2016 UN General Assembly Special Session on Drugs, "to recommend that psychedelics be reclassified as schedule 2 compounds to enable a comprehensive, evidence based assessment of their therapeutic potential."
INFORMATION:
PHILADELPHIA -- HDL is the 'good cholesterol' that helps remove fat from artery walls, reversing the process that leads to heart disease. Yet recent drug trials and genetic studies suggest that simply pushing HDL levels higher doesn't necessarily reduce the risk of heart disease. Now, a team led by scientists from the Perelman School of Medicine at the University of Pennsylvania has shown in a large, forward-looking epidemiological study that a person's HDL function -- the efficiency of HDL molecules at removing cholesterol -- may be a better measure of coronary heart disease ...
A risk gene for dyslexia is associated with impairments in visual motion detection, according to a study published May 27 in The Journal of Neuroscience. Mutations in the gene DCDC2 have previously been associated with dyslexia, and this study found that dyslexics with an altered copy of the gene are unable to detect certain types of visual motion.
The researchers used a series of visual tests to compare typical readers with two groups of dyslexics -- one with and one without a specific deletion in the DCDC2 gene.
The subjects were presented with images of patterned ...
Oklahoma Medical Research Foundation scientists have pinpointed a cell that begins the process of scarring in fatty tissue. The findings cast new light on a biological process that occurs with obesity and can lead to diabetes.
"Scarring can be an important part of the healing process when a person suffers an injury," said OMRF's Lorin Olson, Ph.D., who led the research. "But excessive scarring, or fibrosis, can contribute to many dangerous health conditions."
The new research appears in the June 1 issue of the journal Genes & Development.
Using experimental models, ...
One of the major challenges of cocaine addiction is the high rate of relapse after periods of withdrawal and abstinence. But new research reveals that changes in our DNA during drug withdrawal may offer promising ways of developing more effective treatments for addiction.
Withdrawal from drug use results in reprogramming of the genes in the brain that lead to addictive personality, say researchers from McGill University and Bar Ilan University in a new study published in the Journal of Neuroscience.
"We inherit our genes from our parents and these genes remain fixed ...
New York, NY--May 25, 2015--Under the direction of Latha Venkataraman, associate professor of applied physics at Columbia Engineering, researchers have designed a new technique to create a single-molecule diode, and, in doing so, they have developed molecular diodes that perform 50 times better than all prior designs. Venkataraman's group is the first to develop a single-molecule diode that may have real-world technological applications for nanoscale devices. Their paper, "Single-Molecule Diodes with High On-Off Ratios through Environmental Control," is published May 25 ...
DALLAS, May 26, 2015 -- Drinking two or more alcoholic beverages daily may damage the heart of elderly people, according to research in the American Heart Association journal Circulation: Cardiovascular Imaging.
The study correlated weekly alcohol consumption among 4,466 people -- average age 76 -- to the size, structure and motion of various parts of the heart.
Researchers found:
The more people drank, the greater the subtle changes to the heart's structure and function.
Among men, drinking more than 14 alcoholic beverages weekly (heavy drinking) was linked with ...
DALLAS, May 26, 2015 - A vaccine may one day help lower blood pressure for up to six months, according to new research in the American Heart Association's journal Hypertension.
The study in rats may eventually provide a novel alternative to treat high blood pressure in people, who would not need to take a pill everyday.
"The potential of a vaccine for hypertension offers an innovative treatment that could be very effective for the control of non-compliance which is one of the major problems in the management of hypertensive patients," said Hironori Nakagami M.D., ...
A genetically engineered herpes virus can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action against tumours, a landmark clinical trial has shown.
It is the first time that a phase III trial of viral immunotherapy has definitively shown benefit for patients with cancer.
The trial was led in the UK by researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, and involved 64 research centres worldwide including the University of Oxford.
Researchers randomised 436 patients ...
BOSTON -- Carbon monoxide is known by many as a poisonous gas that causes brain injury and other neurological symptoms, including memory loss and confusion. But a new study led by investigators at Beth Israel Deaconess Medical Center (BIDMC) suggests the opposite may be true: When administered in small, carefully controlled amounts, carbon monoxide may actually protect the brain from damage following subarachnoid hemorrhage, a devastating stroke that results from bleeding in the brain.
Published online today in The Journal of Clinical Investigation (JCI), the new findings ...
WASHINGTON (May 26, 2015) -- The American College of Cardiology's National Cardiovascular Data Registry was the source of data for seven studies published in the first four months of 2015, including a study that identified possible overuse of anticoagulants in low-risk atrial fibrillation patients and research that found a relationship between operator experience and outcomes in certain patients after percutaneous coronary intervention or angioplasty.
CathPCI Registry Study Compares Outcomes of Sleep-Deprived vs. Non-Sleep-Deprived PCI Operators
Only a small number of ...
